Daratumumab for Delayed Red-Cell Engraftment after Allogeneic Transplantation.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 30403942.
- Also identified by DOI 10.1056/NEJMoa1807438.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Daratumumab, a human IgG1κ monoclonal antibody targeting CD38, is used to treat multiple myeloma. We describe successful treatment with daratumumab in a case of treatment-refractory pure red-cell aplasia after ABO-mismatched allogeneic stem-cell transplantation. The patient was a 72-year-old man with the myelodysplastic syndrome who received a transplant from an HLA-matched, unrelated donor with a major ABO incompatibility (blood group A in the donor and blood group O in the recipient). The patient had persistent circulating anti-A antibodies and no red-cell recovery 200 days after transplantation. Standard treatments had no effect. Within 1 week after the initiation of treatment with daratumumab, he no longer required transfusions.
Medical subject headings
- ABO Blood-Group System
- Antibodies, Monoclonal
- Blood Group Incompatibility
- Hematopoietic Stem Cell Transplantation
- Immunologic Factors
- Myelodysplastic Syndromes
- Red-Cell Aplasia, Pure